Matrix-Degrading Enzyme Expression and Aortic Fibrosis During Continuous-Flow Left Ventricular Mechanical Support

• Published in: Journal of the American College of Cardiology 2021-11, Vol.78 (18), p.1782-1795
• Main Authors: Ambardekar, Amrut V., Stratton, Matthew S., Dobrinskikh, Evgenia, Hunter, Kendall S., Tatman, Philip D., Lemieux, Madeleine E., Cleveland, Joseph C., Tuder, Rubin M., Weiser-Evans, Mary C.M., Moulton, Karen S., McKinsey, Timothy A.
• Format: Article
• Language: English
• Subjects: ADAMTS4 Protein - metabolism; aorta; Aortic Diseases - etiology; Aortic Diseases - pathology; Aortic Diseases - physiopathology; Assisted Circulation - adverse effects; Assisted Circulation - instrumentation; Assisted Circulation - methods; congestive heart failure; Extracellular Matrix - enzymology; Female; Fibrosis; Heart Failure - therapy; Heart-Assist Devices - adverse effects; Humans; Immunohistochemistry; left ventricular assist device; Long Term Adverse Effects - pathology; Male; Matrix Metalloproteinases, Secreted - metabolism; mechanical circulatory support; Middle Aged; Sequence Analysis, RNA - methods; vascular remodeling; Vascular Remodeling - physiology
• ISSN: 0735-1097; 1558-3597
• DOI: 10.1016/j.jacc.2021.08.047

The effects of nonphysiological flow generated by continuous-flow (CF) left ventricular assist devices (LVADs) on the aorta remain poorly understood. The authors sought to quantify indexes of fibrosis and determine the molecular signature of post–CF-LVAD vascular remodeling. Paired aortic tissue was collected at CF-LVAD implant and subsequently at transplant from 22 patients. Aortic wall morphometry and fibrillar collagen content (a measure of fibrosis) was quantified. In addition, whole-transcriptome profiling by RNA sequencing and follow-up immunohistochemistry were performed to evaluate CF-LVAD–mediated changes in aortic mRNA and protein expression. The mean age was 52 ± 12 years, with a mean duration of CF-LVAD of 224 ± 193 days (range 45-798 days). There was a significant increase in the thickness of the collagen-rich adventitial layer from 218 ± 110 μm pre-LVAD to 410 ± 209 μm post-LVAD (P < 0.01). Furthermore, there was an increase in intimal and medial mean fibrillar collagen intensity from 22 ± 11 a.u. pre-LVAD to 41 ± 24 a.u. post-LVAD (P < 0.0001). The magnitude of this increase in fibrosis was greater among patients with longer durations of CF-LVAD support. CF-LVAD led to profound down-regulation in expression of extracellular matrix–degrading enzymes, such as matrix metalloproteinase-19 and ADAMTS4, whereas no evidence of fibroblast activation was noted. There is aortic remodeling and fibrosis after CF-LVAD that correlates with the duration of support. This fibrosis is due, at least in part, to suppression of extracellular matrix–degrading enzyme expression. Further research is needed to examine the contribution of nonphysiological flow patterns on vascular function and whether modulation of pulsatility may improve vascular remodeling and long-term outcomes. [Display omitted]